Glaukos Corporation (GKOS) News

Glaukos Corporation (GKOS): $83.04

0.41 (+0.50%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter GKOS News Items

GKOS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GKOS News Highlights

  • GKOS's 30 day story count now stands at 3.
  • Over the past 13 days, the trend for GKOS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest GKOS News From Around the Web

Below are the latest news stories about GLAUKOS Corp that investors may wish to consider to help them evaluate GKOS as an investment opportunity.

Glaukos Announces the Release of its 2020 Sustainability Report

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2020 Sustainability Report. The report highlights the company’s continued commitment and progress on environmental, social and governance (ESG) initiatives. The Sustainability Report can be found on the company’s website here.

Yahoo | April 27, 2021

Glaukos adds presbyopia to existing licensing deal with Intratus

Glaukos Corporation ([[GKOS]] +2.6%) and Intratus, Inc have amended their licensing agreement with Glaukos securing a global exclusive license to use Intratus’ drug delivery platform for the application in the treatment of presbyopia.The financial terms of the agreement were not disclosed.The revised partnership builds ‘upon the promising R&D work we’ve...

Seeking Alpha | April 22, 2021

Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2021 financial results after the market close on Wednesday, May 5, 2021. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 5, 2021.

Yahoo | April 14, 2021

When Should You Buy Glaukos Corporation (NYSE:GKOS)?

While Glaukos Corporation ( NYSE:GKOS ) might not be the most widely known stock at the moment, it received a lot of...

Yahoo | March 24, 2021

Here's Why You Should Retain Glaukos (GKOS) Stock Right Now

Glaukos (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

Yahoo | March 23, 2021

Glaukos to Support World Glaucoma Week with Patient Education Campaign and Free Screening Initiatives

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced two new patient-centric initiatives in honor of World Glaucoma Week. World Glaucoma Week is an annual global initiative championed by the World Glaucoma Association (WGA) to raise awareness surrounding the risk and prevalence of glaucoma. As a proud sponsor of the WGA, Glaukos is launching a global education and awareness campaign and collaborating with eye care institutions across the United States to offer free glaucoma screenings. Both programs are designed to increase glaucoma awareness, testing and diagnosis.

Yahoo | March 8, 2021

Glaukos Announces Participation in Oppenheimer Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021, at 3:10 p.m. EDT.

Yahoo | March 2, 2021

Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos’ Board of Directors will be comprised of nine directors, eight of whom are independent.

Yahoo | March 1, 2021

The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biot...

Benzinga | February 26, 2021

Glaukos Corp (GKOS) Q4 2020 Earnings Call Transcript

GKOS earnings call for the period ending December 31, 2020.

Yahoo | February 26, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6333 seconds.